The U.S. Food and Drug Administration on Thursday permanently lifted its restriction on the abortion pill mifepristone that required providers to dispense the drug in person, allowing it to be delivered by mail. The decision is subject to state laws that can criminalize the practice. But the FDA move could still have significant consequences for women, particularly in rural areas where it might be harder for women to find a clinic or doctor that will administer the drug in person.

RELATED: A post-Roe complication: FDA allows abortion pills to be sent by mail, without in-person consultation